International Journal of DermatologyVolume 60, Issue 4 p. 514-515 Correspondence Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis María F. Ordóñez-Rubiano MD, María F. Ordóñez-Rubiano MD Department of Dermatology, Cayre Clinical Center, Atopic Dermatitis Clinic, Bogotá, Colombia Division of Dermatology, Department of Internal Medicine, Military Central Hospital, Bogotá, ColombiaSearch for more papers by this authorPaula C. Rubiano-Mojica MD, Corresponding Author Paula C. Rubiano-Mojica MD [email protected] Division of Dermatology, Department of Internal Medicine, Military Central Hospital, Bogotá, ColombiaSearch for more papers by this authorMirian Casas MD, Mirian Casas MD Department of Dermatology, Cayre Clinical Center, Atopic Dermatitis Clinic, Bogotá, ColombiaSearch for more papers by this author María F. Ordóñez-Rubiano MD, María F. Ordóñez-Rubiano MD Department of Dermatology, Cayre Clinical Center, Atopic Dermatitis Clinic, Bogotá, Colombia Division of Dermatology, Department of Internal Medicine, Military Central Hospital, Bogotá, ColombiaSearch for more papers by this authorPaula C. Rubiano-Mojica MD, Corresponding Author Paula C. Rubiano-Mojica MD [email protected] Division of Dermatology, Department of Internal Medicine, Military Central Hospital, Bogotá, ColombiaSearch for more papers by this authorMirian Casas MD, Mirian Casas MD Department of Dermatology, Cayre Clinical Center, Atopic Dermatitis Clinic, Bogotá, ColombiaSearch for more papers by this author First published: 28 February 2021 https://doi.org/10.1111/ijd.15499Citations: 7 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechat No abstract is available for this article. References 1Wollenberg A, Flohr C, Simon D, et al. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. Eur Acad Dermatol Venereol 2020; 34: e241–e242. 10.1111/jdv.16411 CASPubMedWeb of Science®Google Scholar 2Ordóñez-Rubiano MF, Campo I, Casas M. Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients. Dermatol Ther 2020; 33: e14172. 10.1111/dth.14172 CASPubMedWeb of Science®Google Scholar 3Cooper TJ, Woodward BL, Alom S, et al. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med 2020; 21: 567–577. 10.1111/hiv.12911 CASPubMedWeb of Science®Google Scholar 4Mahnke Y, Fletez-Brant K, Sereti I, et al. Reconstitution of peripheral T cells by tissue-derived CCR4+ central memory cells following HIV-1 antiretroviral therapy. Pathog Immun 2016; 1: 260–290. 10.20411/pai.v1i2.129 PubMedGoogle Scholar 5Alawadhi A, Karibayeva D, Gottlieb A. Dupilumab in HIV-positive patients: a case series report of 4 patients. JAAD Case Rep 2020; 6: 1356–1359. 10.1016/j.jdcr.2020.09.023 PubMedGoogle Scholar Citing Literature Volume60, Issue4April 2021Pages 514-515 ReferencesRelatedInformation